Cost-Effectiveness Analysis of Pertuzumab with Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States

Published 2019 View Full Article

Authors

Keywords

adjuvant treatment, cost-effectiveness analysis, HER2-positive early breast cancer, pertuzumab, trastuzumab

Journal

VALUE IN HEALTH

Volume -, Issue -, Pages -

Publisher

Elsevier BV

Online

2019-03-12

DOI

10.1016/j.jval.2018.11.014

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now